Brought to you by 
HighLife brings in €32mm via Series B
17 Jan 2019
Executive Summary
HighLife SAS (developing a transcatheter mitral valve replacement system for patients suffering from mitral regurgitation) raised €32mm ($36.6mm) in its Series B financing led by US Venture Partners and Andera Partners, which were joined by Sectoral Asset Management, Sofinnova Partners, and HighLife chairman Jose Calle Gordo. The company will use the funds to finish development of the transcatheter transseptal mitral valve implantation system, including regulatory approval trials in Europe necessary to obtain the CE mark and an early feasibility study in the US. Bryan Garnier & Co. was the placement agent.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
HighLife brings in €32mm via Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice